# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory...
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other ...
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by compe...
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broa...
The FDA has issued a Complete Response Letter to Novo Nordisk's Biologics License Application for once-weekly basal insulin...
In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the review o...
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's T...
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on t...
https://www.dailymail.co.uk/health/article-13620101/ozempic-quitting-patients-weight-loss-effects.html?ns_mchannel=rss&ns_c...